摘要:
The invention provides Neuregulin or a functional fragment thereof for use in a method of preventing, treating or delaying heart failure or preventing cardiac hypertrophy in a mammal, wherein the method comprises releasing Neuregulin to the mammal over a period of 4 hours or longer per day by extended release means such as an osmotic pump, a syringe pump, packaging into a liposome or microsphere or coupling to a polymer.
摘要:
The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.
摘要:
The present invention relates to a neuregulin peptide consisting essentially of or consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:5 as specified herein. The present invention further relates to a pharmaceutical composition comprising the said neuregulin peptide and a pharmaceutically acceptable carrier, excipient, or diluent. The present invention also relates to the said neuregulin peptide for use in a method of treating heart failure in a subject.
摘要:
The present invention relates to an isolated polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 or to the amino acid sequence of SEQ ID NO:25; or encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 25, wherein the polypeptide is capable of phosphorylating myosin light chain. The present invention also relates to an isolated nucleic acid encoding said polypeptide; a composition and a kit comprising the polypeptide or the nucleic acid; a vector comprising the isolated nucleic acid; an isolated host cell comprising the nucleic acid or the vector; an antibody that specifically binds to the polypeptide of the present invention; and a transgenic non-human animal which expresses the nucleic acid of the present invention. The invention further relates to a method of detecting the presence of a nucleic acid of the present invention; and a method of producing a neukinase polypeptide of the present invention.
摘要翻译:本发明涉及分离的多肽,其包含与SEQ ID NO:2的氨基酸序列或SEQ ID NO:25的氨基酸序列具有至少70%同一性的氨基酸序列; 或编码包含SEQ ID NO:2的氨基酸序列或SEQ ID NO:25的氨基酸序列的多肽,其中所述多肽能够磷酸化肌球蛋白轻链。 本发明还涉及编码所述多肽的分离的核酸; 包含所述多肽或所述核酸的组合物和试剂盒; 包含分离的核酸的载体; 包含核酸或载体的分离的宿主细胞; 特异性结合本发明多肽的抗体; 和表达本发明核酸的转基因非人动物。 本发明进一步涉及检测本发明核酸存在的方法; 以及生产本发明的新生素酶多肽的方法。
摘要:
The present invention provides neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury. The present invention demonstrates that neuregulin reduces the infarction size in the rat IRI model, indicating that neuregulin can be used to prevent, treat or delay the myocardial ischemia-reperfusion injury.
摘要:
A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivates, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.